Inflammation

, Volume 37, Issue 4, pp 1167–1178 | Cite as

Protective and Therapeutic Effect of Molsidomine on Bleomycin-Induced Lung Fibrosis in Rats

  • Talat Kilic
  • Hakan Parlakpinar
  • Alaadin Polat
  • Elif Taslidere
  • Nigar Vardi
  • Ediz Sarihan
  • Hilal Ermis
  • Kevser Tanbag
Article

Abstract

We aimed to investigate the preventive and treatment effect of molsidomine (MOL) on bleomycin (BLC)-induced lung injury in rats. Rats were assigned into groups as follows: control group; MOL group, 10 mg/kg MOL was continued orally for 29 day; BLC group, a single intratracheal injection of BLC (2.5 mg/kg), MOL+BLC-preventive group, 10 mg/kg MOL was administered 1 day before the intratracheal BLC injection and continued for 14 days; BLC+MOL-treatment group 10 mg/kg MOL was given on 14th day after the intratracheal BLC injection and continued until sacrifice. All animals were sacrificed on 29th day after BLC administration. The semiquantitative histopathological assessment, tissue levels of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), reduced glutathione (GSH), total antioxidant status (TAS), total oxidant status (TOS), myeloperoxidase (MPO), and oxidative stress index (OSI) were measured. BLC-provoked histological changes were significantly detected compared to the control group. MOL restored these histological damages in different quantity in the treatment and preventive groups. BLC administration significantly decreased levels of GSH and TAS when compared to controls and these reductions was significantly ameliorated by MOL given prophylactic setting. However, therapeutic MOL administration significantly increased the TAS level decreased by BLC. The levels of MDA, MPO, and TOS were significantly increased with BLM, and these augmentations of MDA and TOS were significantly reduced by MOL given prophylactic setting. Furthermore, the OSI was higher in the BLC group, and this increase was reversed by the MOL administration before and after BLC treatment. In this study, both protective and therapeutic effects of MOL against BLC-induced lung fibrosis were demonstrated for the first time.

KEY WORDS

bleomycin pulmonary fibrosis inflammation molsidomine idiopathic pulmonary fibrosis 

Notes

Conflict of Interest

The authors have no conflict of interest to declare. This work has not been supported by grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

  1. 1.
    Raghu, G., H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, J.A. Lasky, et al. 2011. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183: 788–824.PubMedCrossRefGoogle Scholar
  2. 2.
    Gross, T.J., and G.W. Hunninghake. 2001. Idiopathic pulmonary fibrosis. New England Journal of Medicine 345: 517–525.PubMedCrossRefGoogle Scholar
  3. 3.
    Dedon, P.C., and I.H. Goldberg. 1992. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chemical Research in Toxicology 5: 311–332.PubMedCrossRefGoogle Scholar
  4. 4.
    Cottin, V. 2013. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respiratory Research 14(1): 5. doi: 10.1186/1465-9921-14-S1-S5.CrossRefGoogle Scholar
  5. 5.
    Mata, M., A. Ruíz, M. Cerdá, M. Martinez-Losa, J. Cortijo, F. Santangelo, A. Serrano-Mollar, A. Llombart-Bosch, and E.J. Morcillo. 2003. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. European Respiratory Journal 22(6): 900–905.Google Scholar
  6. 6.
    Sogut, S., H. Ozyurt, F. Armutcu, et al. 2004. Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. European Journal of Pharmacology 494: 213–220.Google Scholar
  7. 7.
    Yildirim, Z., Y. Turkoz, M. Kotuk, et al. 2004. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 11: 156–165.Google Scholar
  8. 8.
    Yildirim, Z., M. Kotuk, H. Erdogan, M. Iraz, M. Yagmurca, I. Kuku, and E. Fadillioglu. 2006. Preventive effect of melatonin on bleomycin-induced lung fibrosis in rats. Journal of Pineal Research 40: 27–33.Google Scholar
  9. 9.
    Iraz, M., H. Erdogan, M. Kotuk, M. Yagmurca, T. Kilic, H. Ermis, E. Fadillioglu, and Z. Yildirim. 2006. Ginkgo biloba inhibits bleomycin-induced lung fibrosis in rats. Pharmacological Research 53: 310–316.Google Scholar
  10. 10.
    Akgedik, R., S. Akgedik, H. Karamanli, S. Uysal, B. Bozkurt, D. Ozol, F. Armutcu, and Z. Yildirim. 2012. Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats. Inflammation 35(5): 1732–1741.PubMedCrossRefGoogle Scholar
  11. 11.
    Ermis, H., H. Parlakpinar, G. Gulbas, N. Vardi, A. Polat, A. Cetin, T. Kilic, and Z.A. Aytemur. 2013. Protective effect of dexpanthenol on bleomycin-induced pulmonary fibrosis in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. doi: 10.1007/s00210-013-0908.PubMedGoogle Scholar
  12. 12.
    Gupta, A., S. Sharma, and K. Chopra. 2008. Reversal of iron-induced nephrotoxicity in rats by molsidomine, a nitric oxide donor. Food and Chemical Toxicology 46(2): 537–543.PubMedCrossRefGoogle Scholar
  13. 13.
    Kukovetz, W.R., and S. Holzmann. 1986. Cyclic GMP as the mediator of molsidomine-induced vasodilatation. European Journal of Pharmacology 122: 103–109.PubMedCrossRefGoogle Scholar
  14. 14.
    Valdivielso, J.M., and R.C. Blantz. 2002. Acute renal failure: Is nitric oxide the bad guy? Redox Signaling 4: 925–934.CrossRefGoogle Scholar
  15. 15.
    Walder, C.E., C. Thiemermann, and J.R. Vane. 1991. The involvement of endothelium-derived relaxing factor in the regulation of renal cortical blood flow in the rat. British Journal of Pharmacology 102: 967–973.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Garcia-Criado, F.J., N. Eleno, F. Santos-Benito, et al. 1998. Protective effect of exogenous nitric oxide on the renal function and inflammatory reaction in a model of ischemia-reperfusion. Transplantation 66: 982–990.PubMedCrossRefGoogle Scholar
  17. 17.
    Chander, V., and K. Chopra. 2005. Renal protective effect of molsidomine and l-arginine in ischemia-reperfusion induced injury in rats. Journal of Surgical Research 128(1): 132–139.PubMedCrossRefGoogle Scholar
  18. 18.
    Marios, A.M., and V. Aidinis. 2011. Modeling pulmonary fibrosis with bleomycin. Current Opinion in Pulmonary Medicine 17: 355–361.CrossRefGoogle Scholar
  19. 19.
    Colak, C., and H. Parlakpınar. 2012. Hayvan Deneyleri: In vivo Denemelerin Bildirimi: ARRIVE Kılavuzu-Derleme. Journal of Turgut Ozal Medical Center 19(2): 128–131.CrossRefGoogle Scholar
  20. 20.
    Uchiyama, M., and M. Mihara. 1978. Determination of malonaldehyde precursor in tissues by tiobarbituric acid test. Analytical Biochemistry 34: 271–278.CrossRefGoogle Scholar
  21. 21.
    Sun, Y., L. Oberley, and Y. Li. 1988. A simple method for clinical assay of superoxide dismutase. Clinical Chemistry 34: 497–500.PubMedGoogle Scholar
  22. 22.
    Aebi, H. 1974. Catalase. In Methods of enzymatic analysis, ed. H.U. Bergmeyer, 673–677. New York: Academic.CrossRefGoogle Scholar
  23. 23.
    Paglia, D.E., and W.N. Valentine. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. Journal of Laboratory and Clinical Medicine 70: 158–170.PubMedGoogle Scholar
  24. 24.
    Ellman, G.L. 1959. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82: 70–77.PubMedCrossRefGoogle Scholar
  25. 25.
    Wei, H., and K. Frenkel. 1993. Relationship of oxidative events and DNA oxidation in Sencar mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 14: 1195–1201.PubMedCrossRefGoogle Scholar
  26. 26.
    Erel, O. 2004. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clinical Biochemistry 37: 277–285.PubMedCrossRefGoogle Scholar
  27. 27.
    Erel, O. 2005. A new automated colorimetric method for measuring total oxidant status. Clinical Biochemistry 38: 1103–1111.PubMedCrossRefGoogle Scholar
  28. 28.
    Coward, W.R., G. Saini, and G. Jenkins. 2010. The pathogenesis of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease 4: 367–388.PubMedCrossRefGoogle Scholar
  29. 29.
    Harari, S., and A. Caminati. 2010. IPF: New insight on pathogenesis and treatment. Allergy 65: 537–553.PubMedCrossRefGoogle Scholar
  30. 30.
    Chaudhary, N.I., A. Schnapp, and J.E. Park. 2006. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. American Journal of Respiratory and Critical Care Medicine 173: 769–776. 352006.PubMedCrossRefGoogle Scholar
  31. 31.
    Mungunsukh, O., A.J. Griffin, Y.H. Lee, and R.M. Day. 2010. Bleomycin induces the extrinsic apoptotic pathway in pulmonary endothelial cells. American Journal of Physiology-Lung Cellular and Molecular Physiology 298: 696–703.CrossRefGoogle Scholar
  32. 32.
    Mouratis, M.A., and V. Aidinis. 2011. Modeling pulmonary fibrosis with bleomycin. Current Opinion in Pulmonary Medicine 17: 355–361.PubMedCrossRefGoogle Scholar
  33. 33.
    Sleijfer, S. 2001. Bleomycin-induced pneumonitis. Chest 120: 617–624.PubMedCrossRefGoogle Scholar
  34. 34.
    Valko, M., D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, and J. Telser. 2007. Free radicals and antioxidants in normal physiological functions and human disease. The International Journal of Biochemistry & Cell Biology 39: 44–84.CrossRefGoogle Scholar
  35. 35.
    Cortijo, J., M. Cerda-Nicolas, A. Serrano, G. Bioque, J.M. Estrela, F. Santangelo, et al. 2001. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. European Respiratory Journal 17: 1228–1235.PubMedCrossRefGoogle Scholar
  36. 36.
    Ross, D. 1988. Glutathione, free radicals and chemotherapeutic agents. Pharmacology and Therapeutics 37: 231–249.PubMedCrossRefGoogle Scholar
  37. 37.
    Venkatesan, N., V. Punithavathi, and G. Chandrakasan. 1997. Curcumin protects bleomycin-induced lung injury in rats. Life Sciences 61: L51–L58.CrossRefGoogle Scholar
  38. 38.
    Kang, J.L., W. Park, I.S. Pack, H.S. Lee, M.J. Kim, C.M. Lim, et al. 2002. Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. Journal of Applied Physiology 92: 795–801.PubMedGoogle Scholar
  39. 39.
    Hong-ping, X.I.A., H. Guo-ying, Z.H.U. Jian-xing, and S.U.N. Bo. 2008. Effect of inhalation of nebulized NO donor substance on acute hypoxic lung injury in newborn piglets. Chinese Medical Journal 121(17): 1622–1626.Google Scholar
  40. 40.
    Kinsella, J.P., T.A. Parker, and H. Galan. 1997. Effects of inhaled nitric oxide on pulmonary edema and lung neutophil accumulation in severe experimental hyaline membrane disease. Pediatric Research 41(Pt 1): 457–463.PubMedCrossRefGoogle Scholar
  41. 41.
    Fukatsu, K., H. Saito, I. Han, et al. 1998. Nitric oxide donor decreases neutrophil adhesion in both lung and peritoneum during peritonitis. Journal of Surgical Research 74: 119–124.PubMedCrossRefGoogle Scholar
  42. 42.
    Cao, L., L.L. Qian, Y.R. Zhu, C.B. Guo, X.H. Gong, and B. Sun. 2003. Regulation of activity of nuclear factor-kappa B and activator protein-1 by nitric oxide, surfactant and glucocorticoids in alveolar macrophages from piglets with acute lung injury. Acta Pharmacologica Sinica 24: 1316–1323.PubMedGoogle Scholar
  43. 43.
    Bentli, R., H. Parlakpinar, A. Polat, et al. 2013. Molsidomine prevents cisplatin-induced hepatotoxicity. Archives of Medical Research 44: 521–528.PubMedCrossRefGoogle Scholar
  44. 44.
    Disli, O.M., E. Sarihan, M.C. Colak, et al. 2013. Effects of molsidomine against doxorubicin-induced cardiotoxicity in rats. European Surgical Research 51: 79–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Grisham, M.B. 1995. Interaction between nitric oxide and superoxide: role in modulating leukocyte adhesion in the postischemic microvasculature. Transplantation Proceedings 27: 2842.PubMedGoogle Scholar
  46. 46.
    Clancy, R.M., J. Leszczynska-Piziak, and S.B. Abramson. 1992. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. Journal of Clinical Investigation 90: 1116.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Aoki, F., M. Kurabayashi, Y. Hasegawa, and I. Kojima. 2005. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. American Journal of Respiratory and Critical Care Medicine 172: 713–720.PubMedCrossRefGoogle Scholar
  48. 48.
    Kakugawa, T., H. Mukae, T. Hayashi, H. Ishii, K. Abe, T. Fujii, et al. 2004. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. European Respiratory Journal 24: 57–65.PubMedCrossRefGoogle Scholar
  49. 49.
    Peters, H., et al. 2003. NO mediates antifibrotic actions of l-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney International 64: 509–518.PubMedCrossRefGoogle Scholar
  50. 50.
    Giri, S.N., I. Biring, T. Nguyen, et al. 2002. Abrogation of bleomycin induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice. Nitric Oxide 7: 109–118.PubMedCrossRefGoogle Scholar
  51. 51.
    Chen, X.L., W.B. Li, A.M. Zhou, et al. 2003. Role of endogenous peroxynitrite in pulmonary injury and fibrosis induced by bleomycin A5 in rats. Acta Pharmacologica Sinica 24: 697–702.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Talat Kilic
    • 1
  • Hakan Parlakpinar
    • 2
  • Alaadin Polat
    • 3
  • Elif Taslidere
    • 4
  • Nigar Vardi
    • 4
  • Ediz Sarihan
    • 5
  • Hilal Ermis
    • 1
  • Kevser Tanbag
    • 3
  1. 1.Department of Pulmonary MedicineInonu University School MedicineMalatyaTurkey
  2. 2.Department of PharmacologyInonu University School MedicineMalatyaTurkey
  3. 3.Department of PhysiologyInonu University School MedicineMalatyaTurkey
  4. 4.Department of Embryology and HistologyInonu University School MedicineMalatyaTurkey
  5. 5.Department of Emergency MedicineInonu University School MedicineMalatyaTurkey

Personalised recommendations